Final recommendations

WHO Paediatric Guideline Group meeting
Geneva, SWITZERLAND
Salle D
10 - 11 April 2008
## When to Test

<table>
<thead>
<tr>
<th>Population</th>
<th>HIV-exposed infants</th>
<th>HIV exposure unknown well infant</th>
<th>Well infant UNK EXP Specified settings</th>
<th>Any signs/symptoms</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Reco</strong></td>
<td>Virological testing at 4-6 weeks of age</td>
<td>Ask all about Infant HIV exposure</td>
<td>Ensure Infant/maternal testing in first 6 weeks at first contact with health system</td>
<td>Age appropriate test for all as in WHO PITC</td>
</tr>
<tr>
<td><strong>Strength</strong></td>
<td>STRONG</td>
<td>STRONG</td>
<td>CONDITIONAL (ANC prevalence 1% &gt;and other select settings) (Describe in text)</td>
<td>STRONG</td>
</tr>
</tbody>
</table>
## Recommendations - When to Start ART

<table>
<thead>
<tr>
<th>POPULATION</th>
<th>&lt; 12 mo Confirmed HIV</th>
<th>&lt; 12 mo Presumptive *</th>
<th>1- 4 yrs</th>
<th>≥ 5 yrs</th>
</tr>
</thead>
<tbody>
<tr>
<td>START ART</td>
<td>All with confirmed HIV regardless of clinical/CD4</td>
<td>All</td>
<td>clinical or immunological criteria</td>
<td>clinical or immunological criteria</td>
</tr>
<tr>
<td>Strength of Recommendation</td>
<td>Strong</td>
<td>Strong (Time limited based on performance of algorithms )</td>
<td>Strong</td>
<td>Strong</td>
</tr>
</tbody>
</table>

*If lack ability for viral test, use WHO presumptive diagnosis of HIV – with clinical sx or low CD4 – allows initiation ART based on presumptive dx and stop if found uninfected.

TEXT ONLY - Well infant diagnose late may defer initiation base don CD4/VL
## Recommendations – What to start ART

<table>
<thead>
<tr>
<th>POPULATION</th>
<th>Up to 12 months</th>
<th>1- 4 yrs</th>
<th>≥ 5</th>
</tr>
</thead>
<tbody>
<tr>
<td>START ART</td>
<td>• PMTCT/NVP exposure: PI-regimen</td>
<td>NVP/EFV+ 2NRTI</td>
<td>NVP/EFV+ 2NRTI</td>
</tr>
<tr>
<td></td>
<td>• No PMTCT exposure: NVP-regimen</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Strength of recommendation</td>
<td>Strong</td>
<td>Strong</td>
<td>Strong</td>
</tr>
</tbody>
</table>

**TEXT**
- *3NRTI +NVP, other approaches need research before can be recommended, what to do where NO PI or no cold chain, i.e., no choice use standard NVP*
- Need for research on new strategies in MTCT exposed
- Risks of NVP resistance from any NVP containing ART or MTCT regimens, esp in BF mothers
Dosing

• Approve the work tables and tools and recommendations to date
• Request group to urgently review dosing for < 6 months < 5kg esp for Lop/r and NVP
• EFV data forthcoming
New formulations

• Lop/r sprinkles
• see group C powerpoint
Research/key issues

• See ppt summaries
• Treatment approaches PMTCT failure
• Lop/r PK
• Rifabutin
• Early cotrim
• Care package for infants initiating
• EID operational components
• Retesting strategies
Format and figures of revised recommendations

- short recommendation summaries with evidence tables /summaries and figures made available ASAP
  (asked to take to IMPLEMENTERS/MEXICO)
- Short meeting report (first draft circulated by 25th April)
- Explore/Use new WHO ready to print service
- Would like the summary guideline updated
Dissemination

- WHO Web site - notice of meeting and decision
- Request presentations at upcoming Implementers and Mexico
- Note to all country WR/CO to update them on changes
- Note to GFTAM - ensure TRP considers in Round 8
- Establish small standing committee to communicate regularly and determine need for other review
Other WHO ART/Care recommendations for review

- TB/ART in babies
- EFV for <3
- Switch/failure
- BCG
- INH prophylaxis
- Early cotrim
- Hepatitis in children
Tools/actions required

POC diagnostics,
Dosing charts updated & modified
RNA price negotiations
Clarification of uncertainty relating to RNA DBS
TB diagnostics/drugs for children
lower pricing 2\textsuperscript{nd} line
Thank You

• Chair-Dr. Agnes Mahomva
• All Presenters
• Meeting participants
• TRG members preparing evidence summaries (Mofenson, Abrams, Gibb and others)
• CHER study team for preparatory discussions
• Martina Penazzato & Sally Girvin
• Victoria Anagbo
• ATC and HIV dept staff
• Regional offices
• AFRO RO RPA admin team

Docs all at
ftp://ftp.who.int/pub/Outgoing/Ped%20ART%20Meeting%20docs/
HIV web site